Astera Labs (NASDAQ:ALAB) Trading 9.1% Higher - Here's What Happened

Key Points

• Astera Labs shares jumped 9.1% to approximately $293.56, with about 4.1 million shares traded.
• Analyst sentiment remains positive overall: the stock has a “Moderate Buy” consensus rating and a $348.33 average price target, despite some target reductions and hold ratings.
• The company exceeded quarterly expectations, reporting $0.80 in earnings per share and $392.4 million in revenue, up 104.5% year over year. However, insiders sold roughly $209.7 million of shares over the past quarter.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) shot up 9.1% on Thursday . The stock traded as high as $293.92 and last traded at $293.56. Approximately 4,133,301 shares traded hands during trading, a decline of 21% from the average daily volume of 5,247,150 shares. The stock had previously closed at $269.18.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. UBS Group reissued a "neutral" rating and issued a $425.00 price objective on shares of Astera Labs in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Astera Labs from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 11th. TD Cowen dropped their price target on Astera Labs from $425.00 to $375.00 and set a "hold" rating on the stock in a research note on Wednesday, August 5th. Northland Securities raised shares of Astera Labs from a "market perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research note on Monday, August 17th. Finally, Barclays raised their target price on Astera Labs from $200.00 to $325.00 and gave the company an "equal weight" rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Astera Labs presently has an average rating of "Moderate Buy" and a consensus price target of $348.33.

Astera Labs Price Performance

The stock has a market capitalization of $50.93 billion, a P/E ratio of 145.33 and a beta of 3.77. The company has a 50 day simple moving average of $308.00 and a 200-day simple moving average of $263.90.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.11. The firm had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company's quarterly revenue was up 104.5% on a year-over-year basis. During the same quarter last year, the business earned $0.44 earnings per share. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. As a group, equities analysts forecast that Astera Labs, Inc. will post 2.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Manuel Alba sold 183,000 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $280.13, for a total value of $51,263,790.00. Following the transaction, the director owned 253,863 shares of the company's stock, valued at approximately $71,114,642.19. This represents a 41.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stefan A. Dyckerhoff sold 8,994 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $311.83, for a total value of $2,804,599.02. Following the completion of the transaction, the director owned 3,970 shares in the company, valued at $1,237,965.10. This represents a 69.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 592,244 shares of company stock worth $209,729,973 over the last quarter. Insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Twin Peaks Capital Ltd bought a new position in shares of Astera Labs during the 2nd quarter valued at about $4,830,000. Capstone Financial Advisors Inc. purchased a new position in shares of Astera Labs in the second quarter worth $274,000. Sequoia Financial Advisors LLC raised its position in Astera Labs by 19.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,677 shares of the company's stock valued at $1,776,000 after purchasing an additional 588 shares during the last quarter. Archford Capital Strategies LLC bought a new position in Astera Labs in the 2nd quarter worth $506,000. Finally, Integrated Wealth Concepts LLC lifted its holdings in Astera Labs by 0.7% in the second quarter. Integrated Wealth Concepts LLC now owns 7,006 shares of the company's stock worth $3,384,000 after buying an additional 52 shares during the period. Institutional investors own 60.47% of the company's stock.

About Astera Labs

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data-center operators, system manufacturers and other customers connect, expand and manage the high-speed components used in servers, storage systems and networking platforms.

The company's portfolio includes PCI Express (PCIe) retimers and fabric switches, Compute Express Link (CXL) memory connectivity products, and Ethernet connectivity solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.